 | | Vol. 13.33 – 23 August, 2022 |
| |
|
|
| Since endothelial cells (ECs) can alter drug responses in T cell acute lymphoblastic leukemia (T-ALL), scientists developed an EC/T-ALL co-culture system.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that methionine depletion was a vulnerability in AML that could be exploited therapeutically, and provided mechanistic insight into how cells metabolized and recycled methionine.
[Blood] |
|
|
|
| Investigators demonstrated selectivity and therapeutic efficacy of a potent orally bioavailable multi-functional kinase inhibitor through reduction of downstream kinase activation, amelioration of disease phenotypes, and improved survival in animal models of myelofibrosis.
[Nature Communications] |
|
|
|
| Researchers developed a mesenchymal stromal cell-based co-culture system to optimize transplantation outcome of CRISPR-Cas9 gene-edited human hematopoietic stem and progenitor cells (HSPCs).
[Molecular Therapy] |
|
|
|
| Scientists demonstrated cooperative antileukemic effects of decitabine and all-trans retinoic acid on AML cell lines U937 and MOLM-13.
[Blood Cancer Journal] |
|
|
|
| The authors determined in vitro sensitivity of myelodysplastic syndrome (MDS) patient samples to selective inhibitors of B cell lymphoma-2, BCL-XL and myeloid cell leukemia 1 (MCL1). While venetoclax response positively correlated with MDS with excess blasts, all MDS subtypes responded to MCL1 inhibition.
[Haematologica] |
|
|
|
| Investigators generated novel lineage-specific RNA interference (RNAi) lentiviral vectors, H23B-Ery-Lin-shRNA and H234B-Ery-Lin-shRNA, to probe the functions of genes that exert multifaceted roles in hematopoiesis in erythroid cells without affecting other hematopoietic lineages.
[Scientific Reports] |
|
|
|
| Scientists developed human induced pluripotent stem cell (hiPSC)-engineered niches to reveal druggable cancer-niche dependencies and revealed that mesenchymal and vascular niche-like hiPSC-derived cells supported ex vivo proliferation of patient-derived leukemia cells and mediated treatment resistance.
[Cell Reports Medicine] |
| |
|
|
| The authors analyzed differentially expressed miRNAs in CD34+ chronic myeloid leukemia cells pre- and post-nilotinib therapy from 58 patients enrolled in the Canadian sub-analysis of the ENESTxtnd Phase IIIb clinical trial.
[Leukemia] |
|
|
|
| Following administration of a preparative regimen, researchers infused donor lymphocytes, followed by cyclophosphamide to induce bidirectional tolerance, then infusion of CD34-selected cells.
[Bone Marrow Transplantation] |
|
|
|
| Scientists conducted a matched-pair analysis of post-transplant cyclophosphamide-haplo and umbilical cord blood transplantation using the Japanese registry data.
[Bone Marrow Transplantation] |
|
|
|
| The authors examined changes in serum proteome via high-performance two-dimensional gel electrophoresis during HSC transplantation (HSCT) to search for diagnostic biomarkers for post-HSCT complications.
[Scientific Reports] |
|
|
|
|
| Investigators review populations of osteoblasts at differing stages of differentiation and summarize the current understanding of the role of the osteoblast lineage in supporting hematopoiesis.
[Journal of Bone and Mineral Research] |
|
|
|
| Scientists investigate the results of various articles on the role of natural killer (NK) cells in allogeneic hematopoietic cell transplantation and also their exosomes in graft-versus-leukemia.
[Stem Cell Reviews and Reports] |
|
|
|
|
| Kronos Bio, Inc. announced that the first patient has been dosed in a Phase Ib/II clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML.
[Kronos Bio, Inc.] |
|
|
|
| Each year, Baylor College of Medicine faculty are recognized for their outstanding published scientific contributions to clinical and basic science research over the past three years through the Michael E. DeBakey MD Award for Excellence in Research.
[Baylor College of Medicine] |
|
|
|
|
| October 24 – 26, 2022
Madrid, Spain |
|
|
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | The University of Chicago – Chicago, Illinois, United States |
|
|
|
| | Dalla Lana School of Public Health – Toronto, Ontario, Canada |
|
|
|
| | University of Illinois at Chicago – Chicago, Illinois, United States |
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
